MedTrace Logo

Early Discharge After Primary Percutaneous Coronary Intervention

NCT01860079 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2016-04-07

Study results available
· View outcomes & findings →

Summary

* When Primary percutaneous coronary intervention (PPCI) is performed expeditiously and at a high-volume centre, it is the optimal approach for ST elevation myocardial infarction (STEMI) . In contrast to the clarity of how to treat STEMI, there is no clear definition for when to discharge and which patient to discharge.
* An early discharge strategy may be desired by all parties (financial health care provider, treating physician, nurse, patient, patient's relatives)involved in STEMI.
* The main goal in our study is to test the hypothesis that an early discharge strategy within 48-56 hours in patients with successful PPCI is as safe as in those patients who stay longer (96-120 hours) as of a standard procedure.

Conditions

  • ST Elevation Myocardial Infarction

Interventions

PROCEDURE

early discharge

In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.

Sponsors & Collaborators

  • Acibadem University

    lead OTHER

Principal Investigators

  • Sevket Gorgulu, MD · Acıbadem University School of Medicine

  • Tugrul Norgaz, MD · Acıbadem University School of Medicine

  • Sinan Dagdelen, MD · Acıbadem University School of Medicine

  • Nevzat Uslu, MD · Mehmet Akif Ersoy Education and Training Hospital

  • Aydin Yildirim, MD · Siyami Ersek Educational and Training Hospital

  • Ali Buturak, MD, · Acıbadem University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01860079 on ClinicalTrials.gov